Status:
COMPLETED
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
Lead Sponsor:
University College, London
Collaborating Sponsors:
National University Hospital, Singapore
Singapore Clinical Research Institute (SCRI)
Conditions:
Tuberculosis, Pulmonary
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The current standard management strategy for drug-sensitive pulmonary tuberculosis (TB) is to treat with multiple drugs for 6 months, although patients often fail to adhere to the long treatment, lead...
Eligibility Criteria
Inclusion
- Age 18 to 65 years
- Clinical symptoms consistent with pulmonary TB and/or evidence of pulmonary TB on chest X-ray (CXR)
- Sputum GeneXpert test positive
- Willing to comply with the study visits and procedures
- Resident at a fixed address
- Willing to have directly observed therapy
- Willing and able to provide written informed consent
Exclusion
- Taken more than 10 daily doses of standard anti-TB medication or fluoroquinolones during the 3 months prior to randomisation
- Previous active TB disease for which treatment was given prior to the current episode
- Known or suspected extra-pulmonary TB
- Severe clinical pulmonary TB
- Sputum smear 3+ on microscopy\*
- Cavity size \> 4cm on screening CXR\*
- Presence of rifampicin resistance on GeneXpert test
- Poorly-controlled diabetes that, in the opinion of the investigator, is unlikely to be controlled with available management strategies
- Active malignancy requiring systemic chemotherapy or radiotherapy
- Known Hepatitis B surface antigen positive and/or HCV antibody positive, unless liver function tests consistently within normal range for at least 2 years
- History of myocardial infarction, congestive cardiac failure, cardiac arrhythmias or any known congenital cardiac problems
- History of severe chronic lung disease with symptom score of ≥3 on MRC breathlessness scale
- History of seizures
- Current tendinitis or history of tendinopathy associated with fluoroquinolone use
- Symptomatic peripheral neuropathy causing greater than minimal interference with usual social and functional activities
- Current alcohol or drug abuse
- Women who are currently pregnant or breast-feeding
- Women of childbearing potential unwilling or unable to use appropriate effective contraception for the first 6 months of the trial
- Known allergy to one or more of the study drugs
- Taking a concomitant medication that has a known or predicted interaction with any of the study drugs to which the patient might be randomised, or is known to prolong the QTc interval
- Taking any immunosuppressive drugs or use of systemic corticosteroids for more than 2 weeks prior to screening
- Colour blindness detected by Ishihara test
- 12-lead ECG at screening shows QTc greater than 450ms and/or any other clinically-significant abnormality such as arrhythmia or ischaemia
- Any of the following laboratory parameters at screening:
- Absolute neutrophil \<1000 cells/mL, haemoglobin \<7.0 g/dL, OR platelet count \<50,000 cells/mm3
- Creatinine clearance of \<60ml/min (calculated using Cockcroft-Gault equation)
- ALT greater than 3 times the upper limit of normal
- Uncorrected serum potassium \<3.5 mmol/L
- HIV antibody positive at screening\*
- Any other significant condition (e.g. psychiatric illness, chronic diarrhoeal disease), that would, in the opinion of the investigator, compromise the patient's safety or outcome in the trial or lead to poor compliance with study visits and protocol requirements
- Participation in other clinical intervention trial or research protocol
- Note: \*Criteria may be modified in later stages of the trial
- \-
Key Trial Info
Start Date :
March 21 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2022
Estimated Enrollment :
675 Patients enrolled
Trial Details
Trial ID
NCT03474198
Start Date
March 21 2018
End Date
January 20 2022
Last Update
August 14 2023
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of TB and Respiratory Diseases
New Delhi, India
2
Universitas Padjadjaran
Bandung, Indonesia
3
Persahbahatan Hospital
Jakarta, Indonesia
4
Wahidin Sudirohusodo Hospital
Makassar, Indonesia